134 related articles for article (PubMed ID: 23562150)
21. The discrepancy between patients and informants on clinician-rated measures in major depressive disorder: implications for clinical trials and clinical practice.
Peselow ED; Karamians R; Lord M; Tobia G; IsHak WW
Int Clin Psychopharmacol; 2014 Mar; 29(2):111-5. PubMed ID: 24216755
[TBL] [Abstract][Full Text] [Related]
22. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
24. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
[TBL] [Abstract][Full Text] [Related]
25. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
26. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
27. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
Sakurai H; Suzuki T; Yoshimura K; Mimura M; Uchida H
Psychopharmacology (Berl); 2017 Aug; 234(16):2453-2461. PubMed ID: 28470399
[TBL] [Abstract][Full Text] [Related]
28. Impact of BPRS interview length on ratings reliability in a schizophrenia trial.
Targum SD; Cara Pendergrass J; Toner C; Zumpano L; Rauh P; DeMartinis N
Eur Neuropsychopharmacol; 2015 Mar; 25(3):312-8. PubMed ID: 25554563
[TBL] [Abstract][Full Text] [Related]
29. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.
Fava M; Targum SD; Nierenberg AA; Bleicher LS; Carter TA; Wedel PC; Hen R; Gage FH; Barlow C
J Psychiatr Res; 2012 Dec; 46(12):1553-63. PubMed ID: 22998742
[TBL] [Abstract][Full Text] [Related]
30. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
32. A method to quantify rater bias in antidepressant trials.
Petkova E; Quitkin FM; McGrath PJ; Stewart JW; Klein DF
Neuropsychopharmacology; 2000 Jun; 22(6):559-65. PubMed ID: 10788756
[TBL] [Abstract][Full Text] [Related]
33. Psychometric properties of the Quick Inventory of Depressive Symptomatology (QIDS-SR) in UK primary care.
Cameron IM; Crawford JR; Cardy AH; du Toit SW; Lawton K; Hay S; Mitchell K; Sharma S; Shivaprasad S; Winning S; Reid IC
J Psychiatr Res; 2013 May; 47(5):592-8. PubMed ID: 23419617
[TBL] [Abstract][Full Text] [Related]
34. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
[TBL] [Abstract][Full Text] [Related]
35. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
Arnold LM; Palmer RH; Gendreau RM; Chen W
Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
[TBL] [Abstract][Full Text] [Related]
36. The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients.
Trombello JM; Killian MO; Grannemann BD; Rush AJ; Mayes TL; Parsey RV; McInnis M; Jha MK; Ali A; McGrath PJ; Adams P; Oquendo MA; Weissman MM; Carmody TJ; Trivedi MH
J Psychopharmacol; 2019 Feb; 33(2):185-193. PubMed ID: 30652941
[TBL] [Abstract][Full Text] [Related]
37. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
Tedeschini E; Fava M; Papakostas GI
J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
39. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
40. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews.
Khan A; Faucett J; Brown WA
J Psychiatr Res; 2014 Apr; 51():88-92. PubMed ID: 24477068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
